About Contact Us Careers
Sign In

Epilepsy Market Size & Share, by Diagnosis & Treatment (Imaging Devices, Blood Tests, Anti-Epileptic Drugs); Condition (Drug-Resistant, Intractable); Treatment (First Generation Drugs, Second Generation Drugs, Third Generation Drugs); End-user (Hospitals, Clinics, Ambulatory Surgical Centers, Diagnostic Centers) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2035

  • Report ID: 4084
  • Published Date: Mar 10, 2023
  • Report Format: PDF, PPT

Companies Dominating the Epilepsy Landscape

top-features-companies
      • Stryker B.V.
        • Company Overview
        • Business Strategy
        • Key Product Offerings
        • Financial Performance
        • Key Performance Indicators
        • Risk Analysis
        • Recent Development
        • Regional Presence
        • SWOT Analysis
      • Johnson & Johnson Services, Inc.
      • Novartis AG
      • Pfizer, Inc.
      • Sunovion Pharmaceuticals, Inc.
      • Sanofi aventis Group
      • Koninklijke Philips N.V.
      • Eisai Co. Ltd.
      • Cephalon, Inc.
      • Abbott Laboratories
Browse Key Market Insights with Data Illustration:

In the News

  • Yuyu Pharma along with Novartis Korea joined hands for an agreement in which Yuyu acquired the exclusive distribution rights for 3 prescription medicines, including Tegretol, a medicine containing carbamazepine used to treat conditions including epilepsy.

  •  Koninklijke Philips N.V. announced the acquisition of BioTelemetry, Inc., a leading provider of remote diagnostics and monitoring.

  • Stryker B.V., a leading medical technology company, has finally acquired Wright Medical Group N.V.

     


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4084
  • Published Date: Mar 10, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

The rising prevalence of epilepsy all over the world coupled with an escalation in neurological disorders and rising healthcare expenditure is estimated to boost the market growth.

The market is anticipated to attain a CAGR of 7% over the forecast period, i.e., 2023-2035.

Limited accessibility to treatment in low and middle-income countries is estimated to hamper the market growth.

The market in the North America region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

The major players in the market are Stryker B.V., Johnson & Johnson Services, Inc., Novartis AG, Pfizer, Inc., Sunovion Pharmaceuticals, Inc., Sanofi aventis Group, Koninklijke Philips N.V., Eisai Co. Ltd., Cephalon, Inc., Abbott Laboratories, and other key players.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by diagnosis & treatment, condition, treatment, end-user, and by region.

The hospitals segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.
Inquiry Before Buying Request Free Sample
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying